



Integra LifeSciences Partners With Siemens to Deliver Stereotactic Radiosurgery Solutions

PLAINSBORO, N.J., Nov. 4, 2006 (PRIMEZONE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), today announced that its Radionics business has entered into a preferred partnership with Siemens Medical Solutions Oncology Care Systems, a division of Siemens USA, Inc. (NYSE:SI). Through this partnership, Siemens will be able to offer the Integra Radionics XKnife™ radiosurgery system together with Siemens' linear accelerators to provide full stereotactic capabilities for its radiotherapy customers in the United States.

Radionics and Siemens have been collaborating for many years on both multileaf collimator control and intensity modulated radiation therapy (IMRT) software. This partnership allows proven radiosurgical solutions to be more easily delivered to Siemens' customers. The XKnife™ system includes stereotactic localizers and immobilizers, three-dimensional treatment planning software, radiosurgical collimators, quality assurance instrumentation, training and ongoing support. When combined with the Siemens ModuLeaf 2.5mm multileaf collimator, the XKnife™ system offers the most precise radiation beam shaping available.

Originally developed for treating brain tumors through a collaboration between Radionics and Harvard Medical School, the XKnife™ system is now capable of treating tumors anywhere in the body with improved accuracy. More than 350 XKnife™ radiosurgery systems have been installed worldwide.

Unlike conventional surgery, XKnife™ radiosurgery is completely non-invasive and does not require a surgical incision. Cancerous or other diseased tissue can be treated with focused x-rays that are precisely guided using CT, MRI, and PET images. Surrounding normal tissue is spared and patients are typically able to leave the hospital immediately after their treatment. To date, over 45,000 patients have undergone XKnife™ radiosurgery.

"Radionics has had a strong relationship with Siemens and we look forward to working together more closely to bring the best of both companies to the marketplace," noted Stuart Essig, President and Chief Executive Officer of Integra LifeSciences Holdings Corporation. "By combining Integra's neurosurgical expertise with Siemens's global radiotherapy presence, this partnership will help make radiosurgery available to more hospitals and patients."

"We are excited about the opportunity to be aligned with Integra and the XKnife™ radiosurgery system," says Holger Schmidt, President of Siemens Oncology Care Systems. "Our combined offering provides a complete radiosurgical solution and this preferred partnership makes it easier for our customers to acquire these capabilities. Customers can be assured that they will be getting a proven system."

The XKnife™ system is currently sold in the United States through the Integra NeuroSciences® sales organization. The preferred partnership with Siemens provides an additional distribution channel for the XKnife™ system.

Integra NeuroSciences® is a leading provider of implants, devices, instruments, and systems used in neurosurgery. Integra NeuroSciences®' direct selling effort in North America and Europe currently involves more than 150 professionals. In other markets, Integra NeuroSciences products are sold through a network of distributors.

Integra LifeSciences Holdings Corporation is a diversified medical technology company that develops, manufactures, and markets medical devices for use in a variety of applications. The primary applications for our products are neurosurgery, reconstructive surgery and general surgery. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. Our corporate headquarters are in Plainsboro, New Jersey, and we have manufacturing and research facilities located throughout the world. Please visit our website at <http://www.Integra-LS.com>.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning future clinical uses of the Integra Radionics XKnife Radiosurgery System. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use the XKnife™ System may affect the prospects for its use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the Risk Factors section of Integra's Annual Report on Form 10-K for the year ended December 31, 2005, and information contained in subsequent filings with the Securities and Exchange Commission, could affect actual results.

CONTACT: Integra LifeSciences Holdings Corporation
John B. Henneman, III, Executive Vice President
Chief Administrative Officer

(609) 936-2481

jhenneman@Integra-LS.com

Gianna Sabella, Public Relations Manager

(609) 936-2389

gsabella@integra-LS.com